Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$66.17 USD
-1.63 (-2.40%)
Updated May 23, 2024 04:00 PM ET
After-Market: $66.15 -0.02 (-0.03%) 7:58 PM ET
5-Strong Sell of 5 5
B Value C Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GILD 66.17 -1.63(-2.40%)
Will GILD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) Announces Positive Interim Results on PBC Drug
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Other News for GILD
Analysts’ Top Healthcare Picks: Scholar Rock Holding (SRRK), Gilead Sciences (GILD)
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
3 Biotech Stocks to Buy Now: May 2024
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
Gilead Sciences (GILD) Gets a Hold from Wells Fargo